重大公告
Clarification on new article by Economy Daily News dated Jun 16, 2019
Date of occurrence of the event: Jun 16, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
OBI-888 completes Phase I safety evaluation and demonstrates its safety and tolerability with no major concerns
Date of occurrence of the event: Jun 15, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Announcement of the company’s cash capital increase and base date
Date of occurrence of the event: Jun 14, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head …
Board of directors of the company waived subscription rights exceeding half of the total subscribable shares. Shares to be subscribed by designated persons
Date of occurrence of the event: Jun 10, 2019 Reason for the forfeiture of subscription rights by the directors and supervisors: Overall investment strategy and …
Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
Date of occurrence of the event: May 06, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …